NRP1 and breast cancer: Another study targeted the NRP1/TGB3 axis, a novel mechanism in breast cancer cell line BT-474 correlating high NRP1 with TNC/ITGβ3 signaling but decreases the ABCG2 expression, thereby sensitizing BT-474 NRP1 cells to Adriamycin/cyclophosphamide [171].